Amendment No. 3 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • August 13th, 2024 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 3 to the Research Collaboration Agreement (the “Amendment”) is entered into as of April 3, 2024 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022 and Amendment No. 2 to the Research Collaboration Agreement entered into as of March 8, 2023 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
Amendment No. 4 to the RESEARCH Collaboration AgreementResearch Collaboration Agreement • August 13th, 2024 • Nkarta, Inc. • Pharmaceutical preparations
This Amendment No. 4 to the Research Collaboration Agreement (the “Amendment”) is entered into as of May 2, 2024 (“Amendment Effective Date”) by and between Nkarta, Inc. (“Nkarta”) and CRISPR Therapeutics AG (“CRISPR”). Nkarta and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Research Collaboration Agreement, entered into as of May 5, 2021, between Nkarta and CRISPR and as amended by that certain Amendment No. 1 to the Research Collaboration Agreement entered into as of May 4, 2022, Amendment No. 2 to the Research Collaboration Agreement entered into as of March 8, 2023, and Amendment No. 3 to the Research Collaboration Agreement entered into as of April 3, 2024 (collectively, the “Agreement”). Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.
